Clinical Trials Directory

Trials / Unknown

UnknownNCT04937309

Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea

Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea in Patients With Breast Cancer Receiving Anthracycline and Cyclophosphamide Chemotherapy

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
338 (estimated)
Sponsor
University Hospital, Tours · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Despite pharmaceutical innovations, chemotherapy induced nausea is frequent and largely participating to alter our patients quality of life. Non invasive vagal stimulation is approved in other health issues, for example in headache or gastroparesis, with a reported benefit on nausea. This study aims to analyse if a non invasive vagal stimulation could better prevent chemotherapy induced nausea, in addition to standard treatment, in breast cancer patients treated with cyclophosphamide and anthracycline.

Detailed description

Despite pharmaceutical innovations, chemotherapy induced nausea is frequent and largely participating to alter our patients quality of life. Non invasive vagal stimulation is approved in other health issues, for example in headache or gastroparesis, with a reported benefit on nausea. This study aims to analyse if a non invasive vagal stimulation could better prevent chemotherapy induced nausea, in addition to standard treatment, in breast cancer patients treated with cyclophosphamide and anthracycline.

Conditions

Interventions

TypeNameDescription
DEVICEnon invasive auricular vagal stimulationStimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles
DRUGusual medical treatmentStandard anti emetic treatments to prevent emesis due to chemotherapy
DEVICEsham stimulationStimulation twice a day, beginning the day before until the fourth day after chemotherapy, for the three first chemotherapy cycles, with a sham device

Timeline

Start date
2022-06-24
Primary completion
2024-02-15
Completion
2024-05-01
First posted
2021-06-24
Last updated
2023-05-11

Locations

8 sites across 1 country: France

Source: ClinicalTrials.gov record NCT04937309. Inclusion in this directory is not an endorsement.